Pharmaceutical

Eyenovia acquires US licencing rights for Formosa’s topical eye steroid

Eyenovia hopes for near-term revenue from the licencing deal, with APP13007’s PDUFA date set for 4 March 2024.

Aug 16, 2023 - 20:00
Eyenovia acquires US licencing rights for Formosa’s topical eye steroid
Eyenovia hopes for near-term revenue from the licencing deal, with APP13007’s PDUFA date set for 4 March 2024.
Read the original article

Tags:

Previous Article

Diffusion Pharma’s stockholders support merger with EIP Pharma

Next Article

Amicus gears up to launch Pompe disease combination therapy in the UK

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients

Opinion: STAT+: How to make the EU’s new Joint Clinical...

Oct 20, 2023

STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro

STAT+: Lilly complains to the U.S. International Trade ...

Oct 20, 2023

Tourmaline shifts focus to developing anti-IL6 antibody following merger

Tourmaline shifts focus to developing anti-IL6 antibody...

Oct 21, 2023